Overview

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Status:
Terminated

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

To investigate the long-term safety and tolerability of clobazam when administered for 1 year as adjunctive therapy in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Clobazam